Gnubiotics has gained allowance from the European Patent Office (EPO) for patent application of our microbiome markers for prediction, identification and treatment of pet obesity.

This patent will enable a new standard in animal care and provide broad protections for our REVELAbiome, a microbiome test that will include our patented biomarkers of obesity and leanness in cats. We believe that early detection and predictive microbome based modalities could provide more effective methods for management of chronic diseases in our pets.

At Gnubiotics Sciences we are driven by innovation and passion, which is why this recognition means so much to us.

Read full article